Home IssueArtificial Intelligence Accelerating Data-Driven Drug Development

Accelerating Data-Driven Drug Development

by Joshua New

From screening chemical compounds to optimizing clinical trials to improving post-market surveillance of drugs, the increased use of data and better analytical tools such as artificial intelligence hold the potential to transform drug development, leading to new treatments, improved patient outcomes, and lower costs. However, several obstacles, particularly a lack of access to data, prevent the United States from achieving the full promise of data-driven drug development. Whether policymakers act to overcome these challenges will have a significant impact on both the well-being of Americans and the competitiveness of the United States.

Join the Center for Data Innovation for the release of a new report exploring opportunities to accelerate data-driven innovation in drug development and a panel discussion about the ways data can make drug development faster, more efficient, and lead to new cures.

Date and time:

  • Wednesday, September 18 from 1:00-2:30 PM EST


  • Center for Data Innovation, 1101 K Street NW, Suite 610, Washington, DC 20005.


  • Dr. Chris Austin, Director of the National Center for Advancing Translational Sciences, National Institutes of Health
  • Dr. Bradford Casey, Associate Director of Research Programs, Michael J. Fox Foundation
  • Dr. Subha Madhavan, Director of the Innovation Center for Biomedical Informatics, Georgetown University Medical Center
  • Joshua New, Senior Policy Analyst, Center for Data Innovation (moderator)

View slides.

This event will be recorded and live streamed. Follow the discussion on Twitter with the hashtag #datainnovation.

You may also like

Show Buttons
Hide Buttons